A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Age
18 years - 99 years
Gender
All
participants needed
10
Location
1
A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Brief description of study

This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: B Acute Lymphoblastic LeukemiaLymphoblasts 5 Percent or More of Bone Marrow Nucleated CellsRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaT Acute Lymphoblastic Leukemia
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 830092
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research